Please assess the completion status of the following clinical trial:

Trial Title: Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors

Study Design Characteristics:
- Allocation: None
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed malignant solid tumor that did not respond to or relapsed after standard first-line chemotherapy or other antineoplastic therapy (if the standard therapy for the tumor is generally recognized to be beneficial)~  * Must have been initially diagnosed with malignancy prior to 25 years of age~ * Radiographic, nuclear image, or biopsy confirmation of disease within the past 4 weeks~* Meets one of the following criteria:~  * Phase I: Relapsed/refractory malignant solid tumor (excluding CNS tumors)~    * Patients with recurrent or metastatic disease that was completely resected just prior to study entry are eligible~ * Phase II: Patients are stratified according to one of the following diagnoses:~    * Stratum A: Relapsed sarcoma (rhabdomyosarcoma, osteosarcoma, or Ewing sarcoma)~   * Stratum B: Other relapsed solid tumors, including any of the following:~      * Other soft tissue sarcomas~     * Kidney tumors~     * Lymphoma~     * CNS tumors\*~     * Other solid tumors (neuroblastoma, gonadal and germ cell tumors, liver tumors, or miscellaneous tumors)~   * Stratum C: Newly diagnosed, poor-risk metastatic sarcoma consisting of unresectable pulmonary metastases (≥ 6 nodules) and/or disease involving multiple bones or other organs NOTE: \*Patients with recurrent primary CNS tumors are eligible for the phase II portion of this study provided there are no significant intratumoral bleeding toxicities seen in either COG pediatric phase I studies of dasatinib or the phase I portion of this study~* Radiographically measurable disease (Phase II)~  * Measurable disease is not required for patients who are enrolled in the phase I portion of this study~* No bone marrow involvement (Phase I)~  * Patients with bone marrow involvement are eligible for the phase II portion of this study provided they are not known to be refractory to red cell or platelet transfusions~PATIENT CHARACTERISTICS:~* Lansky performance status (PS) 50-100% (patients 1-16 years of age) or Karnofsky PS 50-100% (patients \> 16 years of age)~* Life expectancy ≥ 8 weeks~* ANC \> 1,000/μL~* Platelet count \> 75,000/μL~* Creatinine clearance or GFR ≥ 70 mL/min OR creatinine \< 1.5 times upper limit of normal (ULN)~* Bilirubin \< 1.5 times ULN for age~* SGOT or SGPT \< 2.5 times ULN for age (\< 5 times ULN if liver involvement by tumor)~* Ejection fraction normal by MUGA OR shortening fraction \> 28%~* No evidence of cardiac arrhythmias requiring therapy~* Corrected QTc interval \< 450 msecs~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* Able to comply with the safety monitoring requirements of this study~* No uncontrolled infection~* No swallowing dysfunction that would preclude oral medication intake~  * Gastric or jejunal tube allowed provided it is functioning~* No history of significant bleeding disorder unrelated to cancer, including the following:~  * Diagnosed congenital bleeding disorders (e.g., von Willebrand's disease)~ * Acquired bleeding disorder diagnosed within the past year (e.g., acquired anti-factor VIII antibodies)~ * Ongoing or recent (within the past 3 months) significant gastrointestinal bleeding~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics~* Recovered from all prior therapy~* At least 7 days since prior and no concurrent drugs known to cause Torsades de Pointes, including the following:~  * Procainamide or disopyramide~ * Amiodarone, sotalol, ibutilide, or dofetilide~ * Erythromycin or clarithromycin~ * Chlorpromazine, haloperidol, mesoridazine, or thioridazine~ * Bepridil, droperidol, methadone, arsenic, chloroquine, domperidone, halofantrine, levomethadyl, pentamidine, sparfloxacin, or lidoflazine~* At least 3 weeks since prior chemotherapy (6 weeks for nitrosourea-containing therapy)~* At least 3 months since prior ifosfamide, carboplatin, and/or etoposide phosphate in the exact combination and dosage as administered in this study~* More than 7 days since prior filgrastim (G-CSF), sargramostim (GM-CSF), or interleukin-11~* More than 14 days since prior pegfilgrastim~* More than 30 days since prior epoetin alfa~* No prior cranial-spinal irradiation at doses \> 2,400 cGy~* No prior radiotherapy, including total-body irradiation, to \> 50% of the bone marrow space~* No other concurrent investigational drugs or anticancer agents~* No concurrent enzyme-inducing anticonvulsants (e.g., phenytoin, phenobarbital, felbamate, primdone, oxcarbazepine, or carbamazepine)~* No concurrent anti-thrombotic or anti-platelet agents (e.g., warfarin, heparin, low molecular weight heparin, aspirin, ibuprofen, or other NSAIDs)~* No concurrent CYP3A4 inhibitors (e.g., itraconazole, ketoconazole, or voriconazole)~* No concurrent highly active antiretroviral therapy for HIV-positive patients~* No concurrent St. John's wort~* No IV bisphosphonates during the first 8 weeks of dasatinib therapy

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 25 Years
- Healthy Volunteers: f

Study Arms:
- Dasatinib with Ifosfamide, Carboplatin, Etoposide (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).